Mr. Morelle (for himself, Mr. Gottheimer, Mr. Pfluger, and Mr. Kean) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Next Generation Medicines Act of 2026. H.R. 8857. 119th
Cong., 2nd
sess., Introduced in House May 15, 2026. https://www.govinfo.gov/app/details/BILLS-119hr8857ih.
APA
Congress, House of Representatives (2026, May 15). Next Generation Medicines Act of 2026 (H.R. 8857 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr8857ih.
MLA
United States, Congress, House of Representatives. Next Generation Medicines Act of 2026. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr8857ih. 119th Congress, H.R. 8857, Introduced in House 15 May. 2026.
Bluebook
H.R.8857 - 119th Congress (2025-2026): Next Generation Medicines Act of 2026, H.R.8857, 119th Cong. (2026), https://www.govinfo.gov/app/details/BILLS-119hr8857ih.
